Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 14/20 | 0.54 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1339152 | 0.86 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL1339339 | 0.85 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL2930345 | 0.83 | HCRTR1 (0.49) | HCRTR1HCRTR2P2RX7KDM4E | |
| SCHEMBL1339577 | 0.83 | HCRTR1 (0.49) | HCRTR1HCRTR2P2RX7KDM4E | |
| SCHEMBL2930343 | 0.83 | HCRTR1 (0.49) | HCRTR1HCRTR2P2RX7KDM4E | |
| SCHEMBL1398678 | 0.83 | HCRTR1 (0.55) | HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL1340523 | 0.79 | HCRTR1 (0.48) | HCRTR1HCRTR2ALDH1A1LMNAHPGD | |
| SCHEMBL1338111 | 0.78 | HCRTR1 (0.77) | HCRTR1HCRTR2 | |
| SCHEMBL1339871 | 0.76 | HCRTR1 (0.76) | HCRTR1HCRTR2 | |
| SCHEMBL1339449 | 0.76 | HCRTR1 (0.75) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063099-B2 | Trans-3-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | HCRTR1 1/4885HCRTR2 2/4885ALDH1A1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.